why choose us

Clinical Trials Search

Showing 6,960 of 132,085 result(s)
Health-Related Quality of Life Outcomes and Bleeding Rates Among Patients With Severe Hemophilia A on Emicizumab

Status: NOT_YET_RECRUITING

Condition: Hemophilia A

Interventions: Emicizumab in Hemophilia A

Date: 2023-10-23

Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis

Status: Completed

Condition: Toxic Epidermal Necrolysis

Interventions: Solu-Medrol® 1 mg;kg body weight intravenous infusion per day in combination with Arocitinib tablets 200 mg per day for 2 weeks

Date: 2023-10-23

Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1568 in Healthy Adult Volunteers

Status: Completed

Condition: Healthy Volunteers

Interventions: One tablet of DWJ1568

Date: 2023-10-23

Drug-drug Interactions Between DWC202313 and DWC202314 in Healthy Subjects

Status: Completed

Condition: Drug Drug Interaction

Interventions: Experimental Drug 1

Date: 2023-10-23

Effects of the Shared-decision Making Training Program

Status: COMPLETED

Condition: Competence

Interventions: A 20-hour tailored SDM combined with EBP training program consisting of a seven-hour lecture and a four-hour hands-on practice session.

Date: 2023-10-23

Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

Status: Completed

Condition: Systemic Lupus Erythematosus

Interventions: Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide

Date: 2023-10-23

PRecisiOn Medicine In StrokE: Evolution of Plasma Brain-Derived Tau in Acute Stroke

Status: NOT_YET_RECRUITING

Condition: Stroke

Interventions: Plasma levels of BD-tau will be assessed using a single-molecule array assay.

Date: 2023-10-23

First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients

Status: Completed

Condition: Carcinoma, Ovarian Epithelial

Interventions: Olaparib is considered the study treatment.
Olaparib tablets will be taken at the dose of 300 mg (2 x 150 mg tablet) twice daily adding to bevaci

Date: 2023-10-23

Study of B;F;TAF in Participants Switching From CAB + RPV to B;F;TAF for HIV-1 Infection (EMPOWER)

Status: COMPLETED

Condition: HIV-1-infection

Interventions: Tablets administered without regard to food

Date: 2023-10-23

Effect of Maolactin on Gastrointestinal Tract (GIT) Health

Status: COMPLETED

Condition: Gastrointestinal Dysfunction

Interventions: Once daily dose of 2 capsules (2 capsules containing 250mg active proteins per capsule; equivalent to 500mg active proteins per day)

Date: 2023-10-23